Florida Senate - 2024                        COMMITTEE AMENDMENT
       Bill No. CS for SB 1320
       
       
       
       
       
       
                                Ì355144!Î355144                         
       
                              LEGISLATIVE ACTION                        
                    Senate             .             House              
                  Comm: RCS            .                                
                  02/08/2024           .                                
                                       .                                
                                       .                                
                                       .                                
       —————————————————————————————————————————————————————————————————




       —————————————————————————————————————————————————————————————————
       The Appropriations Committee on Health and Human Services
       (Calatayud) recommended the following:
       
       
    1         Senate Amendment (with title amendment)
    2  
    3  
    4         Delete lines 102 - 123
    5  and insert:
    6         3. A requirement that the pharmacist maintain records for
    7  any HIV postexposure prophylaxis drugs ordered and dispensed
    8  under the collaborative practice agreement.
    9         4. A process and schedule for the physician to review the
   10  pharmacist’s records and actions under the collaborative
   11  practice agreement.
   12         5. Any other requirements as established by the board, with
   13  the approval of the Board of Medicine and the Board of
   14  Osteopathic Medicine.
   15         (c) A pharmacist authorized to screen for HIV and order and
   16  dispense HIV postexposure prophylaxis drugs pursuant to a
   17  written collaborative practice agreement must provide his or her
   18  supervising physician with evidence of current certification by
   19  the board as provided in subsection (6).
   20         (5) A pharmacist who orders and dispenses HIV postexposure
   21  prophylaxis drugs pursuant to subsection (4) must provide the
   22  patient with written information advising the patient to seek
   23  follow-up care from his or her primary care physician. If the
   24  patient indicates that he or she lacks regular access to primary
   25  care, the pharmacist must comply with the procedures of the
   26  pharmacy’s approved access-to-care plan as provided in
   27  subsection (7).
   28         (6) Before ordering or dispensing HIV postexposure
   29  prophylaxis drugs under this section, a pharmacist must be
   30  certified by the board, according to the rules adopted by the
   31  board and approved by the Board of Medicine and the Board
   32  
   33  ================= T I T L E  A M E N D M E N T ================
   34  And the title is amended as follows:
   35         Delete lines 27 - 28
   36  and insert:
   37         prophylaxis drugs; requiring the board, with approval
   38         of the Board of Medicine and the Board